Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease: Efficacy of Ezetimibe Co-Administered with Ongoing Atorvastatin Therapy in Chd Patients
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
This randomised, double-blind, placebo (PBO)-controlled study evaluated the efficacy and safety of ezetimibe (EZE) co-administered with ongoing atorvastatin (ATV) therapy in 450 hypercholesterolemic patients with coronary heart disease (CHD) who had not achieved their low-density lipoprotein cholesterol (LDL-C) goal < or =2.60 mmol/l while on a stable dose of ATV 10 or 20 mg/day for > or =6 weeks. After a 4-week diet/baseline active run-in period, patients with LDL-C >2.60 mmol/l and < or =4.20 mmol/l were stratified by ATV dose and randomised (1 : 1) to EZE 10 mg or PBO for 6 weeks while continuing open-label ATV. Significantly more patients achieved an LDL-C goal < or =2.6 mmol/l with EZE than PBO (81.3 vs. 21.8%; p < or = 0.001). Compared to PBO, co-administration of EZE with ongoing ATV led to significantly (p < or = 0.001) greater reductions in LDL-C, total cholesterol, triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B; HDL-C was significantly (p < or = 0.05) increased. Co-administration of EZE and ATV was well tolerated, with an overall safety profile similar to ATV alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251
(2001) · European Heart Journal · doi:10.1053/euhj.2001.2610 · Cited by 893
Ballantyne, C. M., Blazing, M. A., King, T. R., Brady, W. E., & Palmisano, J. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.060 · Cited by 202
Cited by
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Jellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Morrone, D., Weintraub, W. S., Toth, P. P., Hanson, M. E., Lowe, R. S., Lin, J., Shah, A. K., & Tershakovec, A. M. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.016 · Cited by 263
Lipid-lowering agents that cause drug-induced hepatotoxicity.
Bhardwaj, S. S., & Chalasani, N. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.06.010 · Cited by 173
Leiter, L. A., Betteridge, D. J., Farnier, M., Guyton, J. R., Lin, J., Shah, A., Johnson‐Levonas, A. O., & Brudi, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01383.x · Cited by 84
Self-citation
Metadata
- Authors
- CRUZ-Fernández, J. M., Bedarida, G. V., Adgey, J., Allen, C., Johnson-Levonas, A. O., & Massaad, R.
- Venue
- International Journal of Clinical Practice
- Publisher
- Hindawi Limited
- Published
- 2005-05-25
- Volume
- 59
- Issue
- 6
- Pages
- 619-627
- ISSN
- 1368-5031 (ISSN-L)
- OpenAlex
- W1502421189
- Cited by
- 51
- References
- 3
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease: Efficacy of Ezetimibe Co-Administered with Ongoing Atorvastatin Therapy in Chd Patients. https://app.cochat.ai/papers/10.1111/j.1368-5031.2005.00565.x
- The paper
- CRUZ-Fernández, J. M., Bedarida, G. V., Adgey, J., Allen, C., Johnson-Levonas, A. O., & Massaad, R. (2005). Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease: Efficacy of Ezetimibe Co-Administered with Ongoing Atorvastatin Therapy in Chd Patients. International Journal of Clinical Practice. https://doi.org/10.1111/j.1368-5031.2005.00565.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.